Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta, Hang Quach (2020). DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-139332.
Article278 days agoA phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results
Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Badros, Jacob P. Laubach, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Dharminder Chauhan, Nancy K. Levin, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results. , 180(1), DOI: https://doi.org/10.1111/bjh.14987.
Article278 days agoPmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
Andrew Spencer, Simon J. Harrison, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Kenneth C. Anderson, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. , 128(22), DOI: https://doi.org/10.1182/blood.v128.22.3326.3326.
Article278 days agoPhase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
Andrew Spencer, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Simon J. Harrison, Amit Khot, Dharminder Chauhan, Kenneth C. Anderson, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2015). Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4220.4220.
Article278 days agoDaratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article23 days ago